We are on a mission to
outsmart cancer resistance.

Theseus is developing next-generation kinase inhibitors to transform the way cancer is treated.

Learn Moredown

Our investigational oncology therapies are designed to address treatment-resistant cancer mutations.

LEARN MORE

Working to deliver best-in-class pan-variant Tyrosine Kinase Inhibitors (TKIs) to cancer patients.

We are developing a pipeline of TKIs designed to inhibit all major cancer causing and drug resistance mutations in clinically significant protein kinases.

LEARN MORE

View our latest news.

View All

Nov 15, 2021

Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

Nov 10, 2021

Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference

Nov 01, 2021

Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
We are building a community working to outsmart cancer resistance. Join us!

SEE OPEN POSITIONS